Cure8 research brief
This review spotlights non-bacterial members of the gut microbiota (viruses and fungi) that may contribute to IBD by altering barrier function, immune responses, and interactions with bacteria. For people with IBD, these findings expand potential biomarker and therapy targets beyond bacteria alone.
Researchers studying the microbiome, clinicians interested in microbiota-directed therapies, and adult patients curious about emerging non-bacterial IBD research
This is a full-text review article summarizing evidence that viral and fungal communities in the gut (the virome and mycobiome) are altered in IBD and interact with bacterial and host immune pathways.
The authors outline recurring findings such as Candida overgrowth, loss of Saccharomyces, expansion of Caudoviricetes phages, and detection of eukaryotic viruses (for example cytomegalovirus, Epstein–Barr virus) in inflamed mucosa, and discuss mechanisms by which these kingdoms may affect barrier integrity and immune signaling.
The review also describes translational directions: biomarker discovery and microbiota-directed therapies that go beyond bacteria, including pre/pro/synbiotics, precision phage therapy, fecal virome transplantation (FVT), and fecal microbiota transplantation (FMT).
The paper highlights technical challenges in studying fungi and viruses (sequencing bias, contamination, incomplete reference databases) and calls for integrated, multikingdom research approaches.
The authors do not present new clinical trial results; the article synthesizes existing studies and outlines opportunities and limitations for future research and therapy development.
This is a narrative review that synthesizes published studies and identifies gaps; it discusses methodological limitations (sequencing biases, contamination, incomplete reference databases) that make interpretation and cross-study comparisons challenging.
Therapeutic approaches mentioned (precision phage therapy, FVT/FMT, synbiotics) are discussed as emerging possibilities rather than established treatments.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: No potential conflicts of interest were disclosed.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Researchers are exploring circRNAs as new molecular players in IBD inflammation; that could lead to future biomarker tests or novel treatments targeting immune pathways relevant to Crohn’s disease and ulcerative colitis.
This study suggests machine learning of stool microbiome data could eventually help distinguish IBD (especially Crohn’s) from healthy people and some other bowel or systemic conditions.
Gut microbes produce small molecules that interact with the host. This study shows lower levels of certain microbial aromatic carboxaldehydes (I3A and 4HBA) in feces from people with Crohn’s disease, suggesting a...
